alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EXHIBIT 32.1

                                  Exhibit 32.1

                                   Form 10-QSB
                             Arete Industries, Inc.
                        Quarter ended September 30, 2005


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


In connection with the Quarterly Report of Arete Industries, Inc. (the
"Company") on Form 10-QSB for the period ending September 30, 2005, as filed
with the Securities and Exchange Commission on the date hereof (the "Report"),
I, Charles Gamber, Chief Executive Officer of the Company, certify, pursuant to
18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley
Act of 2002, that:

     (1) The Report fully complies with the requirements of Section 13(a) or
15(d) of the Securities Exchange Act of 1934; and

     (2) The information contained in the Report fairly presents, in all
material respects, the financial condition and result of operations of the
Company.




Dated:  November 21, 2005           By:  /s/ Charles Gamber
                                         ---------------------------------------
                                         Charles Gamber, Chief Executive Officer
                                         and Director
EX-33.2
(logo) NAVY FEDERAL Credit Union


ASSESSMENT OF COMPLIANCE WITH APPLICABLE SERVICING CRITERIA

Navy Federal Credit Union (the "Company") is responsible for assessing
compliance with the servicing criteria set forth in Item 1122(d) of Regulation
AB promulgated by the Securities and Exchange Commission. The Company has
determined that the servicing criteria are applicable in regard to the
servicing platform for the period as follows:

Platform: The transactions covered by this report include asset-backed
securities transactions consisting of all non-conforming (or Jumbo) loans which
were sold to Charlie Mac and subsequently securitized, beginning on January 1,
2007, for which the Company is acting in the capacity of sub-servicer for Wells
Fargo Bank, NA., as defined in Appendix A.

Applicable Servicing Criteria: The servicing criteria set forth in Item
1122(d)(1)(iv), 1122(d)(2)(i), 1122(d)(2)(ii), 122(d)(2)(iii), 1122(d)(2)(iv),
1122(d)(2)(v), 1122(d)(2)(vi), 1122(d)(2)(vii), 1122(d)(4)(iv), 1122(d)(4)(v),
1122(d)(4)(vi), 1122(d)(4)(vii), 1122(d)(4)(viii), 1122(d)(4)(ix),
1122(d)(4)(x), 1122(d)(4)(xi), 1122(d)(4)(xii), 1122(d)(4)(xiii),
1122(d)(4)(xiv), in regard to the activities performed by the Company with
respect to the Platform (the "Applicable Servicing Criteria"). The Company has
determined that all other servicing criteria set forth in Item 1122(d) are not
applicable to the Platform.

Period: Twelve months ended December 31, 2007 (the "Period").

With respect to the Platform, the Company provides the following assessment of
compliance with respect to the Applicable Servicing Criteria:

1. The Company is responsible for assessing the Company's compliance with the
   Applicable Servicing Criteria as of and for the Period.

2. The company has assessed compliance with the Applicable Servicing Criteria.

3. Based on such assessment, as of and for the Period, the Company has
   complied, in all material respects with the Applicable Servicing Criteria.

PricewaterhouseCoopers LLP, a registered public accounting firm, has issued an
attestation report with respect to the Company's assessment of compliance as of
and for the Period.

NAVY FEDERAL CREDIT UNION

By: /s/ Charles E. Stewart
Charles E. Stewart
Its: Vice President, Secondary Marketing
Dated: January 14, 2008


PO Box 3000 Merrifield VA 22119-3000


(page)


Appendix A

Listing of applicable Trusts (administered by Wells Fargo) and backed by loans
serviced by Navy Federal Credit Union

1. JPMMT 06-S1
2. JPMMT 06-S2
3. JPMMT 06-A6
4. JPALT 06-A6
5. JPMMT 06-S4
6. RBSGC 2007-B
## Contact Information

Bethesda MD20892

huangrk@mail.nih.gov 

July 2017

Back to Top
Exhibit 32.2

CERTIFICATION OF CHIEF FINANCIAL OFFICER  (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.§1350))

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. §1350), the undersigned, Gordon Link, Senior Vice President and Chief
Financial Officer of NaPro BioTherapeutics, Inc. (the "Company") does hereby certify, to his knowledge, that:



Date:
March 11, 2004

| |  | /s/GORDON LINKGordon Link
Senior Vice President and
Chief Financial Officer |  | 
| |  | --------------------------------------------------------------------------- |  | 

A
signed original of this written statement required by Section 906 has been provided to NaPro BioTherapeutics, Inc. and will be retained by NaPro BioTherapeutics, Inc. and
furnished to the Securities and Exchange Commission or its staff upon request.



QuickLinks
```

[Congressional Bills 111th Congress]
[From the U.S. Government Publishing Office]
[S. 2493 Introduced in Senate (IS)]

111th CONGRESS
  1st Session
                                S. 2493

   To extend and modify the temporary suspension of duty on certain 
           machinery for molding or otherwise forming rubber.

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                            October 29, 2009

  Mr. Graham introduced the following bill; which was read twice and 
                  referred to the Committee on Finance

_______________________________________________________________________

                                 A BILL

 
   To extend and modify the temporary suspension of duty on certain 
           machinery for molding or otherwise forming rubber.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. CERTAIN MACHINERY FOR MOLDING OR OTHERWISE FORMING RUBBER.

    (a) In General.--Heading 9902.84.88 of the Harmonized Tariff 
Schedule of the United States (relating to certain machinery for 
molding or otherwise forming rubber) is amended--
            (1) by striking the article description and inserting the 
        following: ``Machinery for molding or otherwise forming 
        uncured, unvulcanized rubber, numerically controlled, the 
        foregoing to be used in production of radial tires designed for 
        off-the-highway use with a rim measuring 63.5 cm or more in 
        diameter (provided for in subheading 4011.20.10, 4011.61.00, 
        4011.63.00, 4011.69.00, 4011.92.00, 4011.94.40, or 4011.99.45), 
        and parts thereof (provided for in subheading 8477.51.00 or 
        8477.90.85)''; and
            (2) by striking ``12/31/2009'' and inserting ``12/31/
        2011''.
    (b) Effective Date.--The amendments made by subsection (a) apply to 
goods entered, or withdrawn from warehouse for consumption, on or after 
the 15th day after the date of the enactment of this Act.
                                 <all>
```
#### In the Matter of the Claim of Otilia Caballero, Appellant, v Fabco Enterprises et al., Respondents. Workers’ Compensation Board, Respondent.

Submitted December 27, 2010;

decided February 22, 2011

Motion for leave to appeal dismissed as untimely *(see*CPLR 5513 [b]).
Exhibit 21

                           BERKELEY TECHNOLOGY LIMITED

                     Subsidiary Listing as of March 31, 2008

Berkeley Technology Limited (Jersey, Channel Islands corporation)

  Berkeley International Capital Limited (Guernsey, Channel Islands corporation)

  Berkeley International Limited (Jersey, Channel Islands corporation)

  Frederick Morgan & Co. Limited (Jersey, Channel Islands corporation)

  London Pacific Advisers Limited (United Kingdom corporation)

  London Pacific Assurance Limited (Jersey, Channel Islands corporation)

       LPAL Investments Limited (Guernsey, Channel Islands corporation)

  London Pacific Trust Company Limited (Jersey, Channel Islands corporation)

       Berkeley (USA) Holdings Limited (California corporation)

             Berkeley Institutional Investment, Inc. (California corporation)

             Berkeley International Capital Corporation (California corporation)

        London Pacific Secretaries Limited (Jersey, Channel Islands corporation)


_____________


Notes:

(1)   Each indentation reflects another tier of ownership.

(2)   All subsidiaries are 100% owned and are listed above,  except that several
      subsidiaries  that in the aggregate are insignificant have been omitted.
Michigan Supreme Court

Lansing, Michigan

Stephen J. Markman,

 Chief Justice

Brian K. Zahra

Bridget M. McCormack

David F. Viviano

Richard H. Bernstein

Kurtis T. Wilder

Elizabeth T. Clement,

Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the 

foregoing is a true and complete copy of the order entered at the direction of the Court. 

 

 

May 25, 2018 

s0522 

Order 

 

Clerk 

May 25, 2018 

157319 

PEOPLE OF THE STATE OF MICHIGAN, 

Plaintiff-Appellant, 

v SC: 157319 

 COA: 333988 

Kalamazoo CC: 2015-001179-FC 

KEVIN DEANDRE WARE, 

Defendant-Appellee. 

_________________________________________/ 

 On order of the Court, the application for leave to appeal the January 9, 2018 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the question presented should be reviewed by this Court.
## Breadcrumb

-  Home 
-  Research 

# Building a Diverse Scientific Workforce

NIDCD is committed to building and sustaining a diverse research workforce. Explore training and funding opportunities, meet NIDCD Diversity Scholars, and read about diversity initiatives from NIDCD Director Debara L. Tucci, M.D., M.S., M.B.A.

## Discover Research Training Opportunities

Training at Labs Across the U.S. (Extramural)
Find individual research opportunities at universities, medical centers, and other institutions.

Training at the NIH Campus (Intramural)
Discover individual research training opportunities on the NIH campus in Bethesda, Maryland.

Institutional Research Training Opportunities
Explore training grants awarded to nonprofit, private, or public institutions in the U.S.

## Explore Funding Announcements

Funding for Research
Discover NIDCD's diversity-focused funding opportunities.

Research Supplements
Find supplemental funding to promote diversity in health-related research.

## Meet Our Scholars

NIDCD Diversity Scholars

In keeping with its goal of enhancing the diversity of the biomedical, behavioral, and clinical research workforce, NIDCD has established the NIDCD Diversity Scholars Program. NIDCD commends its scholars for their hard work and accomplishments.

## Read Messages from the NIDCD Director

NIDCD stands with NIH against structural racism in biomedical research 

Trans-NIH FIRST program will address faculty diversity and inclusion in biomedical research

Affirming our commitment to inclusive excellence in NIDCD research

More Messages

## Editorials on NIDCD's Commitment to Diversity

Leading professional journals have published editorials regarding NIDCD's efforts to build and sustain a diverse research workforce.

Expanding Workforce Diversity and Health Care Equity in Communication Disorders Research: An NIH Institute Director’s Perspective*Journal of the National Black Association for Speech-Language and Hearing*

## Diversity Initiatives Across NIH

                      - Notice of NIH's Encouragement of Applications Supporting Individuals from Underrepresented Ethnic and Racial Groups as well as Individuals with Disabilities
                      - NIH UNITE Initiative to Address Structural Racism
                      - NIH Scientific Workforce Diversity Toolkit
                      - NIH Office of Intramural Training & Education (OITE) Well-Being Resources
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute of Child Health and Human Development Initial Review Group. Pediatrics Subcommittee.                    

*Date:*                         June 18, 2009.                    

*Time:*                         8 a.m. to 5 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         The Legacy, 1775 Rockville Pike, Rockville, MD.                    

*Contact Person:*                         Rita Anand, PhD, Scientific Review Administrator, Division of Scientific Review, National Institute of Child Health, and Human Development, NIH, 6100 Executive Blvd Room 5B01, Bethesda, MD 20892. (301) 496-1487.                         *anandr@mail.nih.gov.*

(Catalogue of Federal Domestic Assistance Program Nos. 93.864, Population Research; 93.865, Research for Mothers and Children; 93.929, Center for Medical Rehabilitation Research; 93.209, Contraception and Infertility Loan Repayment Program, National Institutes of Health, HHS)

Dated: May 18, 2009.

Jennifer Spaeth,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. E9-12209 Filed 5-26-09; 8:45 am]

BILLING CODE 4140-01-P
NOT FINAL UNTIL TIME EXPIRES TO FILE REHEARING MOTION AND, IF FILED, DETERMINED

IN THE DISTRICT COURT OF APPEAL OF FLORIDA SECOND DISTRICT

MOSES GARZA, ) ) Appellant, ) ) v. ) Case No. 2D17-2132 ) STATE OF FLORIDA, ) ) Appellee. ) ___________________________________) Opinion filed August 29, 2018. Appeal from the Circuit Court for Manatee County; Deno Economou, Judge. Paul S. Horning and Marc F. Plotnick of Plotnick Law, P.A., St. Petersburg, for Appellant. Pamela Jo Bondi, Attorney General, Tallahassee, and Jason M. Miller, Assistant Attorney General, Tampa; and Suzanne C. Bechard, Assistant Attorney General, Tampa (substituted as counsel of record), for Appellee.

PER CURIAM.

Affirmed.
KHOUZAM, SALARIO, and BADALAMENTI, JJ., Concur.- 2 -
#### The People of the State of New York, Respondent, v Jeffrey D. Gibson, Appellant.

Submitted August 23, 2010;

decided August 26, 2010

Motion for assignment of counsel granted and David C. Schopp, Esq., the Legal Aid Bureau of Buffalo, Inc., 237 Main Street, Suite 1602, Buffalo, New York 14203 assigned as counsel to the appellant on the appeal herein.
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   YEAR
<FISCAL-YEAR-END>                          DEC-31-1997
<PERIOD-START>                             JAN-01-1997
<PERIOD-END>                               DEC-31-1997
<CASH>                                           1,179
<SECURITIES>                                         0
<RECEIVABLES>                                  124,181
<ALLOWANCES>                                         0
<INVENTORY>                                      4,774
<CURRENT-ASSETS>                                     0
<PP&E>                                          16,426
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                 167,762
<CURRENT-LIABILITIES>                                0
<BONDS>                                         43,819
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                         1,081
<OTHER-SE>                                    (12,366)
<TOTAL-LIABILITY-AND-EQUITY>                   167,762
<SALES>                                         35,626
<TOTAL-REVENUES>                                35,626
<CGS>                                                0
<TOTAL-COSTS>                                        0
<OTHER-EXPENSES>                                42,472
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                              10,121
<INCOME-PRETAX>                               (16,967)
<INCOME-TAX>                                       516
<INCOME-CONTINUING>                           (17,483)
<DISCONTINUED>                                   (297)
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (17,780)
<EPS-PRIMARY>                                   (1.65)
<EPS-DILUTED>                                   (1.65)


</TABLE>
EXHIBIT 32.2

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO SECTION
906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Arête Industries, Inc. (the Company) on
Form 10-Q for the period ending June 30, 2012, as filed with the Securities and Exchange Commission on the date hereof (the Report), I, John Herzog, Interim Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C.
Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



| | (1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
| | --- | ---------------------------------------------------------------------------------------------------------------------



| | (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.
| | --- | ---------------------------------------------------------------------------------------------------------------------------------------------------



|                       |  |  |  |     |  |                                             
|---------------------- |  |  |  | --- |  | --------------------------------------------
|Dated: August 15, 2012 |  |  |  | By: |  | /s/ John Herzog                             
|                       |  |  |  |     |  | John Herzog, Interim Chief Financial Officer
<TABLE> <S> <C>


<ARTICLE>                     5

<S>                             <C>
<PERIOD-TYPE>                  3-MOS
<FISCAL-YEAR-END>              SEP-30-2000
<PERIOD-END>                   DEC-31-1999
<CASH>                               1,148
<SECURITIES>                             0
<RECEIVABLES>                            0
<ALLOWANCES>                             0
<INVENTORY>                              0
<CURRENT-ASSETS>                     1,148
<PP&E>                              22,184
<DEPRECIATION>                      (4,442)
<TOTAL-ASSETS>                     470,475
<CURRENT-LIABILITIES>              584,979
<BONDS>                                  0
<PREFERRED-MANDATORY>                    0
<PREFERRED>                              0
<COMMON>                           837,817
<OTHER-SE>                        (952,321)
<TOTAL-LIABILITY-AND-EQUITY>       470,475
<SALES>                                  0
<TOTAL-REVENUES>                         0
<CGS>                                    0
<TOTAL-COSTS>                      998,878
<OTHER-EXPENSES>                     4,280
<LOSS-PROVISION>                         0
<INTEREST-EXPENSE>                       0
<INCOME-PRETAX>                 (1,003,158)
<INCOME-TAX>                             0
<INCOME-CONTINUING>             (1,003,158)
<DISCONTINUED>                           0
<EXTRAORDINARY>                          0
<CHANGES>                                0
<NET-INCOME>                    (1,003,158)
<EPS-BASIC>                          (.097)
<EPS-DILUTED>                            0



</TABLE>
#### The People of the State of New York, Appellant, v Robert Alonso and Emilia Alonso, Respondents.

Submitted February 14, 2011;

decided February 17, 2011

*768Motion by District Attorneys Association of the State of New York for leave to appear amicus curiae on the appeal herein granted only to the extent that the proposed brief is accepted as filed. Three copies of the brief must be served and an original and 24 copies filed within seven days.
September 1, 2023              TRANSLATIONAL            

Hanna Kim, M.S., M.D.

|

Juvenile Myositis Pathogenesis and Therapeutics Unit

|

## Description

Juvenile dermatomyositis (JDM) is a rare autoimmune disease. It is a chronic condition in most kids, who often experience weakness, skin rash, and inflammation with relatively unpredictable disease course and treatment response. In this study, the researchers used mass spectrometry to analyze the protein contents of urine from kids with JDM, and compared them with samples from healthy controls. They found several differentially expressed proteins, including cathepsin D and galectin-3 binding protein. The levels of these two proteins were higher in the urine from kids with JDM. They also identified some proteins that correlate with clinical measures of disease activity and damage. For example, the levels of cathepsin D in urine positively correlated with disease damage and negatively correlated with results from a muscle disease activity assessment scale.

## What is exciting about this article?

Results from this study suggest that urine analysis may help provide a better understanding of the changes associated with JDM at the protein level. The next step would be to validate the study’s results in larger cohorts. Further, this article shows that urine analysis can be a non-invasive way to study rare diseases such as JDM.

## Grant support

AR041215

Research Areas:
AutoimmunityClinical ResearchComputational BiologyImmunologyMuscle Biology

Reference:

###             Urine proteomics by mass spectrometry identifies proteins involved in key pathogenic pathways in patients with juvenile dermatomyositis.        

62(9).

Research reported in this publication was supported by the Intramural Research Program of the NIHʼs National Institute of Arthritis and Musculoskeletal and Skin Diseases.

Previous

See All Advances

Next

## Recent Advances

Selected recent highlights of NIAMS intramural research:

October 3, 2023

The Transcription Factor STAT4 Controls the Fate of Cytotoxic Innate Lymphocytes

September 26, 2023

Genetic Variants of PLCG2 Cause Immune Dysregulation Through Either Increased or Decreased Function

September 26, 2023

The Microbiomes of People with Recombination-Activating Gene (RAG) Deficiency Have Distinct Features, Including Antimicrobial Resistance Signatures 

September 23, 2023

Neutrophil Extracellular Traps (NETs) Trigger Pathogenic Inflammation and Bone Loss in Periodontitis

September 22, 2023

Possible Mechanism of a Rare Bone Overgrowth Disease Identified

Back to Top